Harvard Pilgrim Health Care | TUFTS Health Plan

Point32Health companies

Payment Policy:

Laboratory: Venous and Arterial Thrombosis Risk Testing

Effective date: Nov. 1, 2025

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products
☐ Tufts Health Plan Commercial products

Public Plans Products

☐ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product)
☐ Tufts Health Together – MassHealth Accountable Care Partnership Plans
☐ Tufts Health RITogether – A Rhode Island Medicaid Plan
☐ Tufts Health One Care – A dual-eligible product

Senior Products

☐ Tufts Health Plan Senior Care Options (SCO) (a dual-eligible product)
☐ Tufts Medicare Preferred HMO/PPO (Medicare Advantage products)

Policy

A thrombosis, also known as a blood clot, occurs within blood vessels in the body. The two main types of thrombosis include venous thrombosis, which is when a vein is blocked due to a blood clot, and arterial thrombosis, which is when an artery is blocked due to a blood clot. Thrombophilias refer to hereditary and/or acquired abnormalities of hemostasis that predispose patients to thrombosis. The most common presentations of venous thromboembolism (VTE) are deep vein thrombosis (DVT) and pulmonary embolism (PE).

Terms such as male and female are used when necessary to refer to sex assigned at birth.

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

1. For individuals without recurrent venous thromboembolism (VTE) risk factors (e.g., surgery, prolonged immobilization, collagen vascular disease, malignancy, certain hematologic disorders), plasma testing for protein C deficiency, protein S deficiency, and antithrombin III deficiency (see **Note 1** and **Note 2**) **MEETS COVERAGE CRITERIA** in any of the following situations:
   a. For individuals less than 50 years of age who have experienced any deep venous thrombosis (DVT) or pulmonary embolism (PE).
   b. For individuals who have experienced a DVT in unusual sites (e.g., hepatic, mesenteric, or cerebral veins).
   c. For individuals who have experienced a DVT and who have a strong family history of thrombotic disease.
   d. For individuals who have experienced a DVT.
   e. For first- and second-degree relatives (see **Note 3**) of individuals who experienced a DVT before 50 years of age.
   f. Before the administration of oral contraceptives, targeted testing of individuals with a personal or family history of DVT.
   g. For pediatric individuals who have suffered from a pediatric arterial ischemic stroke.
2. For individuals with warfarin-induced skin necrosis or for infants who develop neonatal purpura fulminans, plasma testing for protein C deficiency and protein S deficiency (see **Note 1**) **MEETS COVERAGE CRITERIA**.
3. Venous thrombosis risk testing for superficial venous thrombosis (including superficial thrombophlebitis and varicosities) DOES NOT MEET COVERAGE CRITERIA.
4. For all situations, activated protein C (aPC) resistance assay **DOES NOT MEET COVERAGE CRITERIA**.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

5. DVT risk testing as part of a pre-transplant evaluation test **DOES NOT MEET COVERAGE CRITERIA**.

NOTES:
Note 1: Plasma testing for protein C deficiency, protein S deficiency, and antithrombin III deficiency should be performed at least six weeks after the acute thrombotic event and while the patient is not taking anticoagulants.

Note 2: In addition to plasma testing (protein C deficiency, protein S deficiency, antithrombin III deficiency), risk factor testing for individuals suspected of having a hereditary and/or acquired thrombophilia should include genetic testing for Factor V Leiden and Prothrombin gene G20210A mutations.

Note 3: First-degree relatives include parents, full siblings, and children of the individual. Second-degree relatives include grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings of the individual.

Applicable CPT/HCPCS Procedure Codes

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Coding

Code	Description
85300	Clotting inhibitors or anticoagulants; antithrombin III, activity
85301	Clotting inhibitors or anticoagulants; antithrombin III, antigen assay
85302	Clotting inhibitors or anticoagulants; protein C, antigen
85303	Clotting inhibitors or anticoagulants; protein C, activity
85305	Clotting inhibitors or anticoagulants; protein S, total
85306	Clotting inhibitors or anticoagulants; protein S, free
85307	Activated Protein C (APC) resistance assay

Evidence-based Scientific References

6. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41:154-64. doi:10.1007/s11239-015-1316-1
7. Bartholomew JR. Update on the management of venous thromboembolism. Cleveland Clinic journal of medicine. Dec 2017;84(12 Suppl 3):39-46. doi:10.3949/ccjm.84.s3.04
8. Herrmann J. Clinical Cardio-Oncology. Elsevier; 2018.
9. Bauer KA, Lip GY. Overview of the causes of venous thrombosis in adults. Updated March 18, 2026. https://www.uptodate.com/contents/overview-of-the-causes-of-venous-thrombosis-in-adults
10. Byrnes JR, Wolberg AS. Red blood cells in thrombosis. Blood. Oct 19 2017;130(16):1795-1799. doi:10.1182/blood-2017-03-745349
11. Bauer KA. Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity. Updated January 16, 2026. https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity
12. Thompson BT, Kabrhel, Christopher. Overview of acute pulmonary embolism in adults. Updated October 09, 2025. https://www.uptodate.com/contents/overview-of-acute-pulmonary-embolism-in-adults
13. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemost. Nov 2016;42(8):808-20. doi:10.1055/s-0036-1592333
14. Middeldorp S. Factor V Leiden and activated protein C resistance. Updated April 23, 2025. https://www.uptodate.com/contents/factor-v-leiden-and-activated-protein-c-resistance
15. Bauer KA. Protein S deficiency. Updated December 5, 2025. https://www.uptodate.com/contents/protein-s-deficiency
16. Bauer KA. Prothrombin G20210A. Updated May 30, 2025. https://www.uptodate.com/contents/prothrombin-g20210a
17. Bauer KA. Protein C deficiency. Updated January 29, 2026. https://www.uptodate.com/contents/protein-c-deficiency
18. Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017;377(23):2298. doi:10.1056/NEJMc1713797
19. Bauer KA, Stevens SM. Evaluation for thrombophilia and occult malignancy in adults with venous thromboembolism. Updated December 15, 2025. https://www.uptodate.com/contents/evaluation-for-thrombophilia-and-occult-malignancy-in-adults-with-venous-thromboembolism
20. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. Jan 2011;13(1):1-16. doi:10.1097/GIM.0b013e3181faa0f2
21. Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test? Vasc Med. Aug 2018;23(4):388-399. doi:10.1177/1358863x18755927

22. Kujovich JL. Factor V Leiden Thrombophilia. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews((R)). University of Washington, Seattle; 2018.
23. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. Apr 2011;9(2):120-38. doi:10.2450/2010.0066-10
24. NATF. Genetic Risk Factors for Blood Clots and the Role of Genetic Testing. Updated July 21, 2022. https://thrombosis.org/patients/patient-articles/genetic-risk-factors-for-blood-clots-and-the-role-of-genetic-testing
25. Raffini L. Thrombophilia testing in children and adolescents. Updated July 15, 2025. https://www.uptodate.com/contents/thrombophilia-testing-in-children-and-adolescents
26. Curtis C, Mineyko A, Massicotte P, et al. Thrombophilia risk is not increased in children after perinatal stroke. Blood. May 18 2017;129(20):2793-2800. doi:10.1182/blood-2016-11-750893
27. Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2019;50(3)doi:10.1161/str.0000000000000183
28. Lehman LL, Beaute J, Kapur K, et al. Workup for Perinatal Stroke Does Not Predict Recurrence. Stroke. 2017;48(8):2078-2083. doi:10.1161/STROKEAHA.117.017356
29. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol. Jul 2000;110(1):125-9. doi:10.1046/j.1365-2141.2000.02039.x
30. Mäkelburg AB, Veeger NJ, Middeldorp S, et al. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica. Jun 2010;95(6):1030-3. doi:10.3324/haematol.2009.017061
31. Murphy CH, Sabath DE. Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden. Am J Clin Pathol. Feb 4 2019;151(3):302-305. doi:10.1093/ajcp/aqy142
32. Chiasakul T, De Jesus E, Tong J, et al. Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. J Am Heart Assoc. Oct 2019;8(19):e012877. doi:10.1161/jaha.119.012877
33. Ordieres-Ortega L, Demelo-Rodríguez P, Galeano-Valle F, Kremers BMM, ten Cate-Hoek AJ, ten Cate H. Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review. Thrombosis Research. 2020/05/01/ 2020;189:5-12. doi:10.1016/j.thromres.2020.02.009
34. Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. Int J Lab Hematol. May 2017;39 Suppl 1:98-103. doi:10.1111/ijlh.12665
35. Algahtani FH, Stuckey R. High factor VIII levels and arterial thrombosis: illustrative case and literature review. Ther Adv Hematol. 2019;10:2040620719886685. doi:10.1177/2040620719886685
36. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. Jan 2005;3(1):79-84. doi:10.1111/j.1538-7836.2004.01033.x
37. Lee EJ, Dykas DJ, Leavitt AD, et al. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood advances. Jul 11 2017;1(16):1224-1237. doi:10.1182/bloodadvances.2017005249
38. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism. Evidence report/technology assessment. Jun 2009;(180):1-162.
39. Onda S, Furukawa K, Haruki K, et al. d-dimer-based screening for early diagnosis of venous thromboembolism after hepatectomy. Langenbeck's Archives of Surgery. 2021/05/01 2021;406(3):883-892. doi:10.1007/s00423-020-02058-9
40. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. Jul 2021;52(7):e364-e467. doi:10.1161/str.0000000000000375
41. Kang BE, Zhang S, Lesmana H, et al. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.∗97G>A), 2025 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2025;27(8)doi:10.1016/j.gim.2025.101466
42. Zhang S, Taylor AK, Huang X, et al. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. Dec 2018;20(12):1489-1498. doi:10.1038/s41436-018-0322-z
43. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. Feb 2013;15(2):153-6. doi:10.1038/gim.2012.165
44. Bashford MT, Hickey SE, Curry CJ, et al. Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine. 2020/12/01 2020;22(12):2125-2125. doi:10.1038/s41436-020-0843-0
45. ASH. ASH - Testing for thromboembolism | Choosing Wisely. Choosing Wisely https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely
46. Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood advances. 2018;2(22):3226. doi:10.1182/bloodadvances.2018024828
47. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood advances. 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830

48. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood advances. Nov 28 2023;7(22):7101-7138. doi:10.1182/bloodadvances.2023010177
49. King H, Kelley TP, Shatzel JJ. Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk. Hematology. 2024;2024(1):652-663. doi:10.1182/hematology.2024000592
50. ACOG. ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. Obstetrics and gynecology. Sep 2013;122(3):706-17. doi:10.1097/01.AOG.0000433981.36184.4e
51. ACOG. ACOG Practice Bulletin No. 197 Summary: Inherited Thrombophilias in Pregnancy. Obstetrics and gynecology. Jul 2018;132(1):249-251. doi:10.1097/aog.0000000000002705
52. 47.EGAPP. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. Jan 2011;13(1):67-76. doi:10.1097/GIM.0b013e3181fbe46f
53. Gupta A, Sarode R, Nagalla S. Thrombophilia Testing in Provoked Venous Thromboembolism: A Teachable Moment. JAMA Internal Medicine. 2017;177(8):1195-1196. doi:10.1001/jamainternmed.2017.1815
54. Barnes G. Thrombophilia Testing for Provoked VTE. American College of Cardiology; 2017;2019(02/13/2019). https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/06/05/12/46/thrombophilia-testing-in-provoked-venous-thromboembolism
55. Barnes GD. Thrombophilia Testing and Venous Thrombosis. American College of Cardiology; 2017. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/10/20/11/18/thrombophilia-testing-and-venous-thrombosis
56. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. Sep 2019;54(3)doi:10.1183/13993003.01647-2019
57. Mazzolai L, Ageno W, Alatri A, et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. European Journal of Preventive Cardiology. 2022;doi:10.1093/eurjpc/zwab088
58. De Backer J, Haugaa KH, Hasselberg NE, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: Developed by the task force on the management of cardiovascular disease and pregnancy of the European Society of Cardiology (ESC)Endorsed by the European Society of Gynecology (ESG). European Heart Journal. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193
59. WHO. Medical eligibility criteria for contraceptive use: web annex: development of updated recommendations and Grading of Recommendations Assessment, Development and Evaluation (GRADE) tables, 6th ed. https://doi.org/10.2471/B09566
60. NICE. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Updated August 2, 2023. https://www.nice.org.uk/guidance/ng158/chapter/Recommendations
61. Kirsch J, Wu CC, Bolen MA, et al. ACR Appropriateness Criteria® Suspected Pulmonary Embolism: 2022 Update. J Am Coll Radiol. Nov 2022;19(11s):S488-s501. doi:10.1016/j.jacr.2022.09.014
62. Thrombosis Canada. Pulmonary Embolism (PE): Diagnosis. Updated April 30, 2025. https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=PULMONARYEMBOLISMDIAGNOSISANDM
63. Thrombosis Canada. Deep Vein Thrombosis: Diagnosis. Updated May 7, 2025. https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=DEEPVEINTHROMBOSISDIAGNOSIS
64. Thrombosis Canada. Thrombophilia: Deficiencies in Protein C, Protein S and Antithrombin. Updated November 10, 2025. https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=DEFICIENCIESINPROTEINCPROTEINS
65. Thrombosis Canada. Thrombophilia: Factor V Leiden and Prothrombin Gene Mutation. Updated April 30, 2025. https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=THROMBOPHILIAFACTORVLEIDENANDP
66. Thrombosis Canada. Pregnancy: Diagnosis of DVT and PE. Updated January 6, 2026. https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=83
67. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2017;102(11):3869-3903. doi:10.1210/jc.2017-01658

Publication History

08/01/2026: Annual policy review; administrative edits
09/01/2025: Policy created to support coverage guidelines, effective for dates of service beginning Nov. 1, 2025

Background and Disclaimer Information

This policy applies to the products of Harvard Pilgrim Health Care and Tufts Health Plan and their affiliates, as identified in the check boxes on the first page for services performed by contracted providers.

Payment is based on member benefits and eligibility on the date of service, medical necessity review, where applicable, and the provider's network participation agreement with the Plan. As every claim is unique, this policy is neither a guarantee of payment, nor a final indication of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization, and utilization management requirements (when applicable), adherence to Plan policies and procedures, and claims editing logic. An authorization is not a guarantee of payment.

Point32Health reserves the right to amend a payment policy at its discretion. CPT and HCPCS codes are updated as applicable; please adhere to the most recent CPT and HCPCS coding guidelines.

We reserve the right to conduct audits on any provider and/or facility to ensure accuracy and compliance with the guidelines stated in this payment policy. If such an audit determines that a provider/facility did not comply with this payment policy, Harvard Pilgrim Health Care and Tufts Health Plan will expect the provider/facility to refund all payments related to noncompliance.